Profile of Lasmiditan in the Acute Treatment of Migraine in Adults: Design, Development, and Place in Therapy
Drug Design, Development and Therapy · 2023
DOI: 10.2147/dddt.s380440 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Design, Development and Therapy, 2023. Verfasst von Christopher C Anderson und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA. Hauptthemen laut MEDLINE: Serotonin Receptor Agonists, Migraine Disorders. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA.
Zitieren
APA
Anderson, C. C., & VanderPluym, J. H. (2023). Profile of Lasmiditan in the Acute Treatment of Migraine in Adults: Design, Development, and Place in Therapy. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s380440
Vancouver
Anderson CC, VanderPluym JH. Profile of Lasmiditan in the Acute Treatment of Migraine in Adults: Design, Development, and Place in Therapy. Drug Design, Development and Therapy. 2023. doi:10.2147/dddt.s380440
BibTeX
@article{Anderson2023,
author = {Anderson, Christopher C and VanderPluym, Juliana H},
title = {Profile of Lasmiditan in the Acute Treatment of Migraine in Adults: Design, Development, and Place in Therapy},
journal = {Drug Design, Development and Therapy},
year = {2023},
doi = {10.2147/dddt.s380440}
}
EUVIMED